Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis
NCT ID: NCT01785849
Last Updated: 2019-08-26
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
508 participants
INTERVENTIONAL
2013-03-12
2014-06-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
NCT01788046
Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
NCT01785875
Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis
NCT02102204
Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)
NCT03299244
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
NCT01896232
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Etelcalcetide
Participants received etelcalcetide administered by intravenous bolus injection at the end of each hemodialysis session three times a week, for 26 weeks.
Etelcalcetide
Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
Placebo
Participants received placebo administered by intravenous bolus injection at the end of each hemodialysis session, three times per week (TIW) for 26 weeks.
Placebo
Administered intravenously (IV) three times per week.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Etelcalcetide
Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
Placebo
Administered intravenously (IV) three times per week.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is 18 years of age or older.
* Subject must be receiving hemodialysis 3 times weekly for at least 3 months
* Subject agrees to not participate in another study of an investigational agent during the study.
Exclusion Criteria
* Other investigational procedures while participating in this study are excluded.
* Anticipated or scheduled parathyroidectomy during the study period.
* Subject has received a parathyroidectomy within 3 months prior to dosing.
* Anticipated or scheduled kidney transplant during the study period.
* Subject has known sensitivity to any of the products or components to be administered during dosing.
* Subject has participated in a prior clinical trial of AMG 416 (also referred to as KAI-4169).
* Subject has received cinacalcet within the 4 weeks prior to screening labs (treatment with cinacalcet is prohibited during the study).
* Subject has an unstable medical condition based on medical history, physical examination, and routine laboratory tests, or is otherwise unstable in the judgment of the Investigator.
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Amgen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MD
Role: STUDY_DIRECTOR
Amgen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Birmingham, Alabama, United States
Research Site
Pine Bluff, Arkansas, United States
Research Site
Azusa, California, United States
Research Site
Covina, California, United States
Research Site
Lakewood, California, United States
Research Site
Los Angeles, California, United States
Research Site
Lynwood, California, United States
Research Site
Northridge, California, United States
Research Site
Ontario, California, United States
Research Site
Panorama City, California, United States
Research Site
Sacramento, California, United States
Research Site
Whittier, California, United States
Research Site
Pembroke Pines, Florida, United States
Research Site
Meridian, Idaho, United States
Research Site
Evanston, Illinois, United States
Research Site
Springfield, Massachusetts, United States
Research Site
Detroit, Michigan, United States
Research Site
Kalamazoo, Michigan, United States
Research Site
Pontiac, Michigan, United States
Research Site
Southgate, Michigan, United States
Research Site
Tupelo, Mississippi, United States
Research Site
Kansas City, Missouri, United States
Research Site
Reno, Nevada, United States
Research Site
Amherst, New York, United States
Research Site
Brooklyn, New York, United States
Research Site
Rosedale, New York, United States
Research Site
The Bronx, New York, United States
Research Site
Yonkers, New York, United States
Research Site
Chapel Hill, North Carolina, United States
Research Site
Durham, North Carolina, United States
Research Site
Allentown, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Orangeburg, South Carolina, United States
Research Site
Sumter, South Carolina, United States
Research Site
Columbia, Tennessee, United States
Research Site
Nashville, Tennessee, United States
Research Site
Austin, Texas, United States
Research Site
Fort Worth, Texas, United States
Research Site
Fort Worth, Texas, United States
Research Site
Grand Prairie, Texas, United States
Research Site
Houston, Texas, United States
Research Site
Mansfield, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Tyler, Texas, United States
Research Site
Fairfax, Virginia, United States
Research Site
Mechanicsville, Virginia, United States
Research Site
Norfolk, Virginia, United States
Research Site
Bluefield, West Virginia, United States
Research Site
Liverpool, New South Wales, Australia
Research Site
St Leonards, New South Wales, Australia
Research Site
Parkville, Victoria, Australia
Research Site
Prahan, Victoria, Australia
Research Site
Graz, , Austria
Research Site
Linz, , Austria
Research Site
Vienna, , Austria
Research Site
Aalst, , Belgium
Research Site
Baudour, , Belgium
Research Site
Brussels, , Belgium
Research Site
Leuven, , Belgium
Research Site
Liège, , Belgium
Research Site
Brampton, Ontario, Canada
Research Site
Greenfield Park, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Hradec Králové, , Czechia
Research Site
Prague, , Czechia
Research Site
Praha 4 - Nusle, , Czechia
Research Site
Slavkov u Brna, , Czechia
Research Site
Třinec, , Czechia
Research Site
Nantes, , France
Research Site
Poitiers, , France
Research Site
Reims, , France
Research Site
Saint-Ouen, , France
Research Site
Salouël, , France
Research Site
Berlin, , Germany
Research Site
Dresden, , Germany
Research Site
Kiel, , Germany
Research Site
Villingen-Schwenningen, , Germany
Research Site
Baja, , Hungary
Research Site
Budapest, , Hungary
Research Site
Budapest, , Hungary
Research Site
Győr, , Hungary
Research Site
Kaposvár, , Hungary
Research Site
Pécs, , Hungary
Research Site
Ashkelon, , Israel
Research Site
Nahariya, , Israel
Research Site
Tel Aviv, , Israel
Research Site
Milan, , Italy
Research Site
Napoli, , Italy
Research Site
Pavia, , Italy
Research Site
San Fermo Della Battaglia (CO), , Italy
Research Site
Verona, , Italy
Research Site
Bialystok, , Poland
Research Site
Warsaw, , Poland
Research Site
Warsaw, , Poland
Research Site
Warsaw, , Poland
Research Site
Wroclaw, , Poland
Research Site
Zamość, , Poland
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Santander, Cantabria, Spain
Research Site
Barcelona, Catalonia, Spain
Research Site
Barcelona, Catalonia, Spain
Research Site
Madrid, , Spain
Research Site
Madrid, , Spain
Research Site
Cambridge, , United Kingdom
Research Site
Coventry, , United Kingdom
Research Site
Glasgow, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Nottingham, , United Kingdom
Research Site
Salford, , United Kingdom
Research Site
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Block GA, Bushinsky DA, Cunningham J, Drueke TB, Ketteler M, Kewalramani R, Martin KJ, Mix TC, Moe SM, Patel UD, Silver J, Spiegel DM, Sterling L, Walsh L, Chertow GM. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. JAMA. 2017 Jan 10;317(2):146-155. doi: 10.1001/jama.2016.19456.
Kroenke MA, Weeraratne DK, Deng H, Sloey B, Subramanian R, Wu B, Serenko M, Hock MB. Clinical immunogenicity of the d-amino acid peptide therapeutic etelcalcetide: Method development challenges and anti-drug antibody clinical impact assessments. J Immunol Methods. 2017 Jun;445:37-44. doi: 10.1016/j.jim.2017.03.005. Epub 2017 Mar 6.
Stollenwerk B, Iannazzo S, Akehurst R, Adena M, Briggs A, Dehmel B, Parfrey P, Belozeroff V. A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. Pharmacoeconomics. 2018 May;36(5):603-612. doi: 10.1007/s40273-017-0605-2.
Stollenwerk B, Iannazzo S, Cooper K, Belozeroff V. Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy. J Med Econ. 2017 Oct;20(10):1110-1115. doi: 10.1080/13696998.2017.1360309. Epub 2017 Aug 14.
Chen P, Narayanan A, Wu B, Gisleskog PO, Gibbs JP, Chow AT, Melhem M. Population Pharmacokinetic and Pharmacodynamic Modeling of Etelcalcetide in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis. Clin Pharmacokinet. 2018 Jan;57(1):71-85. doi: 10.1007/s40262-017-0550-4.
Block GA, Chertow GM, Sullivan JT, Deng H, Mather O, Tomlin H, Serenko M. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism. PLoS One. 2019 Mar 15;14(3):e0213774. doi: 10.1371/journal.pone.0213774. eCollection 2019.
Cunningham J, Block GA, Chertow GM, Cooper K, Evenepoel P, Iles J, Sun Y, Urena-Torres P, Bushinsky DA. Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. Kidney Int Rep. 2019 Apr 16;4(7):987-994. doi: 10.1016/j.ekir.2019.04.010. eCollection 2019 Jul.
Wolf M, Block GA, Chertow GM, Cooper K, Fouqueray B, Moe SM, Sun Y, Tomlin H, Vervloet M, Oberbauer R. Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. Clin Kidney J. 2019 Apr 26;13(1):75-84. doi: 10.1093/ckj/sfz034. eCollection 2020 Feb.
Hain D, Tomlin H, Gibson C. Administration of Etelcalcetide for the Treatment of Secondary Hyperparathyroidism in Patients with CKD-MBD on Hemodialysis: A Nephrology Nursing Perspective. Nephrol Nurs J. 2019 May-Jun;46(3):315-290.
Related Links
Access external resources that provide additional context or updates about the study.
AmgenTrials clinical trials website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KAI-4169-006
Identifier Type: OTHER
Identifier Source: secondary_id
2012-002805-23
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
20120229
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.